Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population.

Autor:	Ata F; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Yousaf Z; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Zahir FZ; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Mohamed Babiker A; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Ali Farooqi A; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Ahmad Al Hiyari M; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Al Bozom AI; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Mohamed AH; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Nashwan AJ; Department of Nursing for Education & Practice Development, Hamad Medical Corporation, Doha, Qatar., Yassin MA; Department of Medical Oncology/Hematology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Jazyk:	angličtina
Zdroj:	Qatar medical journal [Qatar Med J] 2022 Jul 07; Vol. 2022 (3), pp. 22. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).
DOI:	10.5339/qmj.2022.22
Abstrakt:	Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation. Methods: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care & Research. The study included patients with chronic refractory ITP who received rituximab as second-line therapy. Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort. Results: Of the 41 patients with chronic ITP, 26 were Arabs, 12 were Asians, and 3 were of other ethnicities. Rituximab was associated with an overall response rate of 80.4%. Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%). Asians had a response rate of 66.6%, and adverse effects were seen in 16.7% of the patients. Conclusions: In chronic refractory ITP, rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities. (© 2022 Ata, Yousaf, Zahir, Babiker, Ali Farooqi, Al Hiyari, Al Bozom, Mohamed, Nashwan, Yassin, licensee HBKU Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu